NCT05726383: Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
- State
- Under way
- Phase
- Phase 2
- People
- 32 planned
- Started
- 14 May 2024
- Primary completion
- 31 Dec 2028
- Arms
- Treatment Arm - Iscador*P
- Results
- None posted
- 13 Feb 2023: Trial registered
- 14 May 2024: Trial started